CN104004062B - 关于per2蛋白激动剂多肽及其应用 - Google Patents
关于per2蛋白激动剂多肽及其应用 Download PDFInfo
- Publication number
- CN104004062B CN104004062B CN201410288340.9A CN201410288340A CN104004062B CN 104004062 B CN104004062 B CN 104004062B CN 201410288340 A CN201410288340 A CN 201410288340A CN 104004062 B CN104004062 B CN 104004062B
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- per2
- protein agonist
- cell
- per2 protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 42
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 42
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 42
- 101001073216 Homo sapiens Period circadian protein homolog 2 Proteins 0.000 title claims abstract description 35
- 102100035787 Period circadian protein homolog 2 Human genes 0.000 title claims abstract description 35
- 229940076376 protein agonist Drugs 0.000 title claims description 26
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims abstract description 26
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims abstract description 19
- 201000004101 esophageal cancer Diseases 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 21
- 230000005012 migration Effects 0.000 abstract description 3
- 238000013508 migration Methods 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 abstract description 2
- 238000009509 drug development Methods 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 239000002547 new drug Substances 0.000 abstract description 2
- 230000004083 survival effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 27
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 201000005619 esophageal carcinoma Diseases 0.000 description 11
- 238000012360 testing method Methods 0.000 description 7
- 239000012930 cell culture fluid Substances 0.000 description 6
- 230000012292 cell migration Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 238000011580 nude mouse model Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000000452 restraining effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002626 targeted therapy Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000405217 Viola <butterfly> Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410288340.9A CN104004062B (zh) | 2014-06-25 | 2014-06-25 | 关于per2蛋白激动剂多肽及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410288340.9A CN104004062B (zh) | 2014-06-25 | 2014-06-25 | 关于per2蛋白激动剂多肽及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104004062A CN104004062A (zh) | 2014-08-27 |
CN104004062B true CN104004062B (zh) | 2016-03-16 |
Family
ID=51364990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410288340.9A Active CN104004062B (zh) | 2014-06-25 | 2014-06-25 | 关于per2蛋白激动剂多肽及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104004062B (zh) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1150317C (zh) * | 1999-08-10 | 2004-05-19 | 中国医学科学院肿瘤医院肿瘤研究所 | 一种食管癌相关新基因 |
TW201000119A (en) * | 2008-06-10 | 2010-01-01 | Oncotherapy Science Inc | MYBL2 epitope peptides and vaccines containing the same |
-
2014
- 2014-06-25 CN CN201410288340.9A patent/CN104004062B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN104004062A (zh) | 2014-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105056250B (zh) | 一种microRNA在制备治疗前列腺癌的药物中的应用 | |
CN104004062B (zh) | 关于per2蛋白激动剂多肽及其应用 | |
CN103898087A (zh) | 磁场屏蔽在医疗中的应用 | |
CN116650474A (zh) | 苍耳亭的医药新用途 | |
CN104004056B (zh) | 一种关于Cyclin D蛋白抑制剂多肽及其应用 | |
CN108384757A (zh) | 一种制备人胆囊癌奥沙利铂耐药细胞系的方法 | |
CN104004059B (zh) | 一种关于白介素-33抑制剂多肽及其应用 | |
CN103524567B (zh) | 一种抗人骨肉瘤含锌杂多化合物的应用 | |
CN104045690B (zh) | 生长抑素受体激动剂多肽及其应用 | |
CN106244588A (zh) | 激活肺癌细胞中RUNX3表达的saRNA及其应用 | |
CN104017051B (zh) | 一种Cyclin D 蛋白抑制剂多肽及其应用 | |
CN104086630B (zh) | 一种生长抑素受体激动剂多肽及其应用 | |
CN1762346A (zh) | 雷公藤甲素在制备抗卵巢癌药物中的应用 | |
CN104045689B (zh) | 一种关于生长抑素受体激动剂多肽及其应用 | |
CN103602625B (zh) | 含有重组腺病毒质粒的大肠杆菌及重组腺病毒的应用 | |
CN104004063B (zh) | 一种关于Npas2蛋白激动剂多肽及其应用 | |
CN104045692B (zh) | 一种Npas2蛋白激动剂多肽及其应用 | |
CN113768924B (zh) | 一种能抑制肿瘤细胞的组合物及其相关应用 | |
CN104045691B (zh) | Npas2蛋白激动剂多肽及其应用 | |
CN108379583A (zh) | 一种肿瘤转移药物治疗的靶标及其应用 | |
CN104045693B (zh) | 一种关于per2蛋白激动剂多肽及其应用 | |
CN112972455B (zh) | 一种化合物在制备抗肿瘤药物的应用 | |
CN104004060B (zh) | Cyclin D蛋白抑制剂多肽及其应用 | |
CN104004061B (zh) | 白介素-33抑制剂多肽及其应用 | |
CN106806903B (zh) | 靶向下调lin28基因表达在提高小细胞肺癌化疗敏感性方面的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Liu Yuanchao Inventor after: Wang Xiujuan Inventor after: Shao Wenshan Inventor after: Xu Shiyu Inventor before: Luo Ruixue |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160214 Address after: 266200 Qingdao City, Shandong province Jimo city shop Town, that is, 122 East Road, Jimo Second People's Hospital Applicant after: Liu Yuanchao Address before: High tech Zone Suzhou city Jiangsu province 215000 Chuk Yuen Road No. 209 Applicant before: Suzhou Pu Luo Da Biotechnology Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201020 Address after: 241000 Jishan Town Economic Development Zone, Nanling County, Wuhu City, Anhui Province Patentee after: Nanling County eco tourism Assets Operation Co., Ltd Address before: No.122 Jimo Second People's Hospital, Dianji Town, Jimo City, Qingdao City, Shandong Province Patentee before: Liu Yuanchao |
|
TR01 | Transfer of patent right |